Automated insulin delivery use in children and adolescents with type 1 diabetes across the world
Authors' conclusion
In this large multinational real-world cohort, AID therapy significantly improved glycemic outcomes and reduced hypoglycemia in children and adolescents with T1D. These findings support the effectiveness of AID systems across diverse clinical settings and underscore their value in pediatric diabetes care.
Study context
- Population
- Children and adolescents (≤18 years) with T1D who initiated automated insulin delivery (AID) 2014–2022; SWEET registry, 53 centers in 29 countries
- Participants
- 2,170 children
- Exposure
- 12 months after vs 12 months before AID initiation
- Outcome
- HbA1c, mean sensor glucose and percentages of time in predefined glycemic ranges
- Follow-up
- 12 months before and after AID initiation
Methodological detailsreal-world, multinational, registry-based, before-after (12 months before and after AID initiation)
- Real-world
- Multinational
- Registry-based
- Before-after (12 months before and after AID initiation)
Main finding
As reported in the abstract
Glycemic outcomes
- Time in target range (70-180 mg/dL) and tight target range (70-140 mg/dL) increased with AID
- Mean sensor glucose and glucose variability decreased
- Time below range (<70 mg/dL) was reduced
- HbA1c improved
Observational data: associations, not effects.
Further findings
- No significant change in total daily insulin dose
Original publication
Automated insulin delivery use in children and adolescents with type 1 diabetes across the world. Diabetes Res Clin Pract. Published 8 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →